Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences Announces Approval of First Clinical Trial Application of ARCUS Gene Insertion Program by Partner iECURE

Wednesday, December 13, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences has received approval from the Australian Therapeutic Goods Administration for its ECUR-506 gene insertion program. This marks the first clinical trial application for the ARCUS gene insertion program, developed in partnership with iECURE. The Phase 1/2 study aims to address OTC deficiency, highlighting the potential for innovative gene therapies.
Price reaction · baseline $11.55 (2023-12-12 close) · hit pre-market · clean, no other DTIL news in the window
day 0 close · peak
+2.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Approval of ECUR-506 for clinical trials is a significant milestone.
  • The partnership with iECURE enhances the potential for innovative therapies.
  • The program targets OTC deficiency, addressing a critical medical need.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

– OTC Deficiency Gene Insertion Program, ECUR-506, Receives Clearance from Australian Therapeutic Goods Administration for Phase 1/2 Study DURHAM, N.C. –(BUSINESS WIRE)–Dec. 13, 2023– Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary

Frequently Asked Questions

What is ECUR-506?

ECUR-506 is a gene insertion program developed by Precision BioSciences targeting OTC deficiency.

Who approved the clinical trial for ECUR-506?

The Australian Therapeutic Goods Administration approved the clinical trial for ECUR-506.

What phase is the ECUR-506 study?

The ECUR-506 study is a Phase 1/2 clinical trial.

What partnership is involved in the ECUR-506 program?

The ECUR-506 program is developed in partnership with iECURE.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences iECURE OTC deficiency gene therapy clinical trials
Last updated: Dec 13, 2023

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →